Dose reduction in maxillofacial imaging using low dose Cone Beam CT |
| |
| Institution: | 1. Department of Oral Diagnosis and Oral Radiology, School of Dentistry, University of Athens, Greece;2. Licensing and Inspection Division, Greek Atomic Energy Commission, Greece;1. Department of Plastic and Reconstructive Surgery, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden;2. Department of Clinical Science, Intervention and Technology, Division of Ear, Nose and Throat Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden;1. Nagoya University Graduate School of Medicine, 1-1-20, Daikominami, Higashi-ku, Nagoya, Japan;2. National Cancer Center Hospital East, Department of Radiological Technology, 6-5-1 Kashiwanoha, Kashiwa, Japan;3. National Institutes for Quantum and Radiological Science and Technology, Center for Advanced Radiation Emergency Medicine, Department of Radiation Measurement and Dose Assessment, 4-9-1 Anagawa, Inage-ku, Chiba, Japan;4. National Cancer Center Hospital East, Department of Medical Informatics, 6-5-1 Kashiwanoha, Kashiwa, Japan;5. Canon Medical Systems Corporation, 1385 Shimoishigami, Otawara, Tochigi, Japan;1. Department of Orthodontics, University of Illinois at Chicago, 801 S Paulina St. Rm 131, Chicago, IL 60612;2. Department of Radiology, The University of Chicago, Chicago, IL;3. Department of Oral Medicine and Diagnostic Sciences, University of Illinois at Chicago, Chicago, IL;4. Department of Radiology, University of Illinois at Chicago, Chicago, IL;5. Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL;1. Department of Oral and Craniomaxillofacial Surgery, Technical University of Munich, Klinikum rechts der Isar, Germany;2. Institute for Medical Biometry, Epidemiology and Medical Informatics, University of Saarland, Homburg/Saar, Germany;3. Leeds Teaching Hospitals and St James Institute of Oncology, Leeds General Infirmary, LS1 3EX, UK;1. Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München (LMU Munich), Garching b. München, Germany;2. The Patrick G Johnston Centre for Cancer Research, Queen''s University of Belfast, Northern Ireland Cancer Centre, Belfast, Northern Ireland, United Kingdom;3. University of Lyon, CREATIS, CNRS UMR5220; Inserm U1044, INSA-Lyon, Université Lyon 1, Centre Léon Bérard, Lyon, France;4. University of Lyon, Institute of Nuclear Physics Lyon (IPNL), CNRS UMR 5822, Villeurbanne, France;5. Division of Biomedical Engineering Sciences, Loma Linda University, Loma Linda, CA, United States of America;6. Department of Physics, U. C. Santa Cruz, Santa Cruz, CA, United States of America;7. Department of Radiation Oncology, Department of Medical Physics, University Hospital, LMU Munich, Munich, Germany;8. German Cancer Consortium, (DKTK), Munich, Germany;9. Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America |
| |
| Abstract: | Objectives(a) To measure the absorbed dose at certain anatomical sites of a RANDO phantom and to estimate the effective dose in radiographic imaging of the jaws using low dose Cone Beam computed tomography (CBCT) and (b) to compare the absorbed and the effective doses between thyroid and cervical spine shielding and non-shielding techniques.Study designThermoluminescent dosimeters (TLD-100) were placed at 14 sites in a RANDO phantom, using a Cone Beam CT device (Newtom, Model QR-DVT 9000, Verona, Italy). Dosimetry was carried out applying two techniques: in the first, there was no shielding device used while in the second one, a shielding device (EUREKA!, TRIX) was applied for protection of the thyroid gland and the cervical spine. Effective dose was estimated according to ICRP60 report (EICRP). An additional estimation of the effective dose was accomplished including the doses of the salivary glands (ESAL). A Wilcoxon Signed Ranks Test was used for statistical analysis.ResultsIn the non-shielding technique the absorbed doses ranged from 0.16 to 1.67 mGy, while 0.32 and 1.28 mGy were the doses to the thyroid and the cervical spine, respectively. The effective dose, EICRP, was 0.035 mSv and the ESAL was 0.064 mSv. In the shielding technique, the absorbed doses ranged from 0.09 to 1.64 mGy, while 0.18 and 0.95 mGy were the respective values for the thyroid and the cervical spine. The effective dose, EICRP, was 0.023 mSv and ESAL was 0.052 mSv.ConclusionsThe use of CBCT for maxillofacial imaging results in a reduced absorbed and effective dose. The use of lead shielding leads to a further reduction of the absorbed doses of thyroid and cervical spine, as well as the effective dose. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
